On December 11, 2025, Climb Bio, Inc. entered into an agreement with RA Capital to exchange 20,440,000 shares of common stock for a pre-funded warrant to purchase the same number of shares, giving RA Capital 23.0% voting power post-transaction. This filing indicates a significant adjustment to the company's capital structure.